Women's Health: Worldwide Prescription Drug Markets, 4th Edition

Women's Health: Worldwide Prescription Drug Markets, 4th Edition
Kalorama Information
August 1, 2006
408 Pages
Pub ID: KLI1190853
US $3,900.00 Online Download
US $3,900.00 Hard Copy Mail Delivery
US $7,800.00 Global Site License
US $4,200.00 Online Delivery plus 1 Hard Copy
Abstract
The past 25 years have seen unprecedented advancements in the area of women?s health. A number of events have helped to bring the concerns of women?s health to the forefront of medicine but the most significant was the women?s health movement, which increased attention to women?s health issues and the shortcomings of traditional medical practice and research. The National Institutes of Health, the American Medical Association, and the Office of Research on Women?s Health were all instrumental in affecting changes. Large studies are now conducted to gather data on the prevention and treatment of the major causes of death in middle-aged and older women, including cancer and osteoporosis. A number of societies have been established to bring attention to serious shortcomings and unmet needs in women?s health research worldwide with the focus on the study of diseases that affect only women and the secondary influence of reproduction on other physiological systems. Thanks to insistent congresswomen, women?s health activists, pressure from advocacy groups like the National Women?s Health Network and the Public Citizen?s Health Research Group, women?s health issues have risen to the public awareness.
The market for prescription drugs to treat the constellation of conditions that make up the discipline of women?s health has follow right along with the consciousness raising efforts. Since Kalorama?s last edition of this study, not only have revenues grown almost across all sectors, but the R&D pipeline has virtually exploded, setting up both great potential for the years ahead and some difficult competitive challenges.
This report provides market size, growth, and share for the following product categories:
Autoimmune diseases
Cancer
Gynecological and Sexually Transmitted Diseases
Hormones
Osteoporosis
Urinary Disorders
Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers? level. Data are expressed in current U.S. dollars. The base year for data was 2005. Historical data are provided for each of the years 2000 through 2005, and forecast data are provided for each of the years 2006 through 2010. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2005 base year.
In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.
The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women?s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 36 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women?s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.
Comments: 0
Votes:28